{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-157038","form_type":"8-K/A","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2026-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.047033+00:00","generated_at":"2026-05-15T06:09:41.933059+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.75,"confidence":"high","headline":"Sensei Biotherapeutics files audited Faeth financials; net loss $16M in 2025, going-concern doubt","bullets":["Faeth net loss $16.0M in 2025 ($18.3M in 2024); accumulated deficit $77.7M at Dec 31, 2025.","R&D expenses $12.0M (2025) vs $14.1M (2024); cash & equivalents $20.4M at Dec 31, 2025.","Auditor cites substantial doubt about going concern due to potential cash payments from $200M PIPE Series B preferred.","Acquisition of Faeth closed Feb 17, 2026; concurrent $200M PIPE closed Feb 20, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-157038","json":"https://secwatch.observer/filing/0001193125-26-157038.json","markdown":"https://secwatch.observer/filing/0001193125-26-157038.md","text":"https://secwatch.observer/filing/0001193125-26-157038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526157038/0001193125-26-157038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526157038/d40329d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:09:41.933059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}